TITLE

Risk of cancer in patients receiving insulin glargine

AUTHOR(S)
Dawson, Leslie K.; Hamilton, Leslie A.
PUB. DATE
December 2010
SOURCE
American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p2025
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The risk of malignancy in patients using insulin glargine was evaluated. Summary. Patients with diabetes mellitus have increased rates of cancers including breast, colon, and pancreatic cancers. Since nondiabetic patients with increased levels of insulin have similar rates of the same cancers, hyperinsulinemia could be key. Normally, insulin produces metabolic effects and insulin-like growth factor-I (IGF-I) produces mitogenic effects. Since the molecules are structurally similar, it is possible for insulin to act like IGF-I, promoting mitogenicity. Concern that insulin may promote the growth of some cancers is heightened with insulin analogues, since changing the structure of human insulin could produce molecules with increased mitogenic potential. In vivo, insulin glargine has been shown to have greater mitogenic potential than human insulin. It is unknown whether this occurs in vitro, because the insulin glargine molecule is transformed once injected. Studies published in 2009 suggest that patients on insulin glargine could be at greater risk for cancer than patients on other antidiabetes therapies, but the trial results are conflicting. In response, the Food and Drug Administration, American Diabetes Association, American Association of Clinical Endocrinologists, and European Association for the Study of Diabetes have formally stated that patients should continue to use insulin glargine until more information is available. Conclusion. Studies on the relationship between insulin glargine and cancer have been inconclusive.
ACCESSION #
55612806

 

Related Articles

  • New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence. Miller, Brien Rex; Hanh Nguyen; Jia-Haur Hu, Charles; Chihyi Lin; Quang T. Nguyen // American Health & Drug Benefits;Nov2014, Vol. 7 Issue 8, p452 

    BACKGROUND: Diabetes is a deadly and costly disease. The number of adults in the United States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current pace, 1 in 3 US adults will have diabetes in their lifetime. Currently, 14 classes of drugs are available to treat...

  • Insulin therapy in type 2 diabetes — update. Hill, Jill // Diabetes & Primary Care;2012, Vol. 14 Issue 3, p163 

    Insulin therapy is ultimately required by many people with type 2 diabetes. Unlike in type 1 diabetes, the aim of insulin therapy in people with type 2 diabetes is initially to supplement the endogenous insulin produced by pancreatic beta-cells against a background of insulin resistance. Over...

  • Setting up the structured Pump Advanced Carbohydrate Education programme. Cardwell, Jan; O'Brien, Sarah; Wessels, Lara; Hardy, Kevin; Furlong, Niall // Journal of Diabetes Nursing;2011, Vol. 15 Issue 7, p274 

    Enabling patients to have a say in the design and delivery of local health services is a key priority in the NHS. The St Helens and Knowsley Teaching Hospitals NHS Trust diabetes team aimed to set up a peer support group for people with type 1 diabetes to aid in carbohydrate counting while on...

  • Choose Your Foods: Exchange Lists for Diabetes: The 2008 Revision of Exchange Lists for Meal Planning. Geil, Patti Bazel // Diabetes Spectrum;Fall2008, Vol. 21 Issue 4, p281 

    The article focuses on the revisions made to Exchange Lists for Meal Planning for diabetes in 2008. The Exchange Lists for Meal Planning has been designed as an education tool for diabetes nutrition, in which it assigns foods into groups that can be exchanged or traded within a group due to...

  • INSULIN ADMINISTRATION.  // Monthly Prescribing Reference;Mar2014, Vol. 30 Issue 3, p78 

    A table is presented which lists several insulin injections and drugs including the Insulin Injection Regular (R), the Insulin Lispro and the Insulin Isophane Suspension (NPH) along with their brand names, administration and mixing insulins.

  • INSULINS.  // Monthly Prescribing Reference;Mar2014, Vol. 30 Issue 3, p81 

    A table is presented which lists several insulin injections and drugs including the Insulin Injection Regular (R) from Eli Lilly & Co., the Insulin Lispro from Eli Lilly & Co. and the Insulin Glulisine from Sanofi-Aventis SA along with their brand names, route and duration.

  • Insulin protocols for hospital management of diabetes. Farquhar, Andrew // Canadian Family Physician;Oct2007, Vol. 53, p1668 

    The article presents information on the medical protocols that are carried out to improve the management of diabetes in hospitals. The basal-bolus approach, which steers from the use of sliding scale regular insulin is discussed, along with the function of the treatment. It is mentioned that...

  • Evaluation of guidelines for oral therapy in T2D.  // Diabetes Digest;2012, Vol. 11 Issue 2, p78 

    The article discusses the research conducted to check if the guidelines on oral medications for T2D are consistent which depends on the quality of guideline development.

  • Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Blair, Hannah; Keating, Gillian // Drugs;Mar2016, Vol. 76 Issue 3, p363 

    Insulin glargine 300 U/mL (Toujeo) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus), with a duration of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics